Trials / Completed
CompletedNCT02676843
Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Columbia University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The study will investigate the ability of a new PET tracer, 18F-AV-1451, to detect depositions of a protein, called tau, in the brains of people with a mutation in the tau gene that causes deposition of the protein, and in people without the mutation. Up to three 18F-AV-1451 scans will be performed (one per year) on control subjects without MAPT mutations, presymptomatic mutation carriers, and symptomatic mutation carriers.
Detailed description
Approximately 40% of cases of Frontotemporal lobar Degeneration (FTLD) are also associated with abnormal deposition of tau protein. The purpose of this study is to image MAPT mutation carriers and their non-carrier relatives in order to study the use of this tracer as a biomarker in Frontotemporal Lobar Degeneration with tau deposition (FTLD-tau).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 18F-AV-1451 | A single injection of up to 10 millicuries of 18F-AV-1451 will be administered to subjects, followed by a 20-minute PET scan. |
Timeline
- Start date
- 2016-04-01
- Primary completion
- 2018-11-25
- Completion
- 2018-11-25
- First posted
- 2016-02-08
- Last updated
- 2019-12-06
- Results posted
- 2019-12-06
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02676843. Inclusion in this directory is not an endorsement.